Market Access The critical importance of payer-provider collaboration goes... The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January.
Market Access Medicare drug pricing negotiations: What comes next? Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the
Market Access The benefits of ePI for patients and the planet With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.
Market Access Life sciences real estate is booming amid looming ‘patent cl... The life sciences sector across Europe has remained remarkably resilient in recent years, with record levels of growth and investment.
Market Access Changing Faces: Agency, consultancy, and investor hires for ... Just a quick write-up this month for agency, consultancy, and investor hires.
Market Access Balancing innovation and safety: The impact of Medtech regul... The Medtech sector is currently at a crossroads, facing a potential choice between rapid technological advancement and strict regulatory oversight.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.